Clinical Genomics Sequencing Service Laboratories: A Procurement Guide
Clinical genomics sequencing has moved from research novelty to standard of care across oncology, rare disease diagnosis, and pharmacogenomics. Hospital pathology directors and pharma R&D leads selecting a sequencing partner must navigate a landscape of over 800 CLIA-certified laboratories—each with distinct panel coverage, platform capabilities, and accreditation profiles.
Accreditation Landscape
All laboratories performing clinical sequencing in the United States must hold CLIA certification under the Clinical Laboratory Improvement Amendments. Most high-throughput labs additionally pursue CAP accreditation from the College of American Pathologists and ISO 15189 certification. For labs reporting results used in FDA-regulated companion diagnostics, additional FDA approval or clearance of specific assays (e.g., FoundationOne CDx, Guardant360 CDx) is required.
Key Selection Criteria
- Panel Coverage
- Ranges from targeted panels (50–500 genes) to whole exome sequencing (WES) and whole genome sequencing (WGS). Oncology-focused labs typically offer both tissue-based and liquid biopsy panels.
- Turnaround Time
- Standard TAT ranges from 7–21 calendar days depending on assay complexity. Rapid panels for actionable mutations can deliver results in 3–5 days.
- Sequencing Platform
- Illumina NovaSeq and NextSeq dominate the clinical market. Long-read platforms from PacBio and Oxford Nanopore are gaining traction for structural variant detection and HLA typing.
- Bioinformatics Pipeline
- Clinical-grade variant calling, annotation against ClinVar/OMIM, and integration with institutional EHR systems differentiate top-tier labs.
Market Segments
| Segment | Representative Labs | Primary Application |
|---|---|---|
| Comprehensive Genomic Profiling | Foundation Medicine, Tempus, Caris Life Sciences | Oncology treatment selection |
| Liquid Biopsy | Guardant Health, Natera, Exact Sciences | MRD monitoring, early detection |
| Hereditary Genetics | Invitae (Labcorp), Myriad Genetics, GeneDx | Carrier screening, rare disease |
| Full-Service NGS | GENEWIZ (Azenta), Novogene, Fulgent Genetics | WES/WGS, custom panels |
| Academic Medical Centers | Broad Clinical Labs, Baylor HGSC, WashU GTAC | Translational research, clinical trials |
Regulatory Considerations
Labs offering laboratory-developed tests (LDTs) operate under CLIA enforcement discretion, while FDA-cleared/approved tests carry a defined regulatory pathway. The evolving VALID Act framework may reshape how LDTs are regulated, making it critical for procurement teams to assess each lab's regulatory posture when selecting a long-term partner.